- Home
- TERN vs RNA Comparison
TERN vs RNA Comparison
Compare TERN & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TERN | RNA |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 2.3B |
| IPO Year | 2021 | 2025 |
Fundamental Metrics
Financial Performance| Metric | TERN | RNA |
|---|---|---|
| Price | $42.72 | $16.40 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 20 |
| Target Price | $48.60 | ★ $69.26 |
| AVG Volume (30 Days) | 1.7M | ★ 3.0M |
| Earning Date | 04-17-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.81 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $88.12 |
| Revenue Next Year | N/A | $18.11 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.87 | $13.06 |
| 52 Week High | $48.26 | $73.06 |
Technical Indicators
Market Signals| Indicator | TERN | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 68.48 | 4.22 |
| Support Level | $39.15 | N/A |
| Resistance Level | $48.26 | $72.52 |
| Average True Range (ATR) | 2.08 | 0.66 |
| MACD | 0.28 | -6.96 |
| Stochastic Oscillator | 96.50 | 5.68 |
Price Performance
Historical ComparisonAbout TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. The company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.